SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Ringing in the New Year
January 31, 2008
 · 
5 min read
Genetown
BB Biotech AG Invested 9.5% of its Portfolio in Biogen Idec, Inc. (Massachusetts)
October 16, 2007
 · 
1 min read
Job Trends
Beantown/Genetown and Beyond: Biotechnology in Massachusetts
September 13, 2007
 · 
11 min read
Drug Development
No New Brain Infection Cases with MS Drug Biogen Idec, Inc. (Massachusetts)'s Tysabri
August 28, 2007
 · 
1 min read
Genetown
Icahn May Boost Biogen Idec, Inc. (Massachusetts) Stake, Forecasts Takeover
August 27, 2007
 · 
1 min read
Biotech Beach
The Day In Review: Genentech, Inc. Adds To Pipeline, Again
January 9, 2007
 · 
1 min read
Genetown
The Day In Review: Cambrex Corporation Sells Bio Businesses For $460 Million
October 24, 2006
 · 
1 min read
Genetown
The Day In Review: Biogen Idec Buys Another MS Drug
October 3, 2006
 · 
1 min read
The Day In Review: News On Multiple Sclerosis Drugs
September 28, 2006
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More